Helix BioPharma Corp., a clinical-stage oncology company, announced on Wednesday the appointment of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, effective immediately. The strategic moves are designed to bolster the company's capital markets and governance capabilities as it prepares for a planned uplisting to the Nasdaq Stock Market through the Multijurisdictional Disclosure System (MJDS).
Stadnyk, former TSX Life Sciences Lead and a biotech capital markets executive, brings over 15 years of experience in biotechnology, capital markets, and public company leadership. He previously served as Head of Life Sciences at the TSX and TSXV, advising biotech issuers, boards, and institutional investors on public listings, capital formation, and strategic positioning. Over his career, he has led and supported over $100 million in institutional financings and contributed to strategic transactions including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth.
Butterworth is a seasoned corporate governance professional with more than 15 years of experience supporting public and private companies in governance and regulatory compliance across multiple jurisdictions, including the pharmaceutical, technology, and finance sectors. Based in British Columbia, both appointees strengthen Helix's Canadian capital markets and governance expertise as the company advances its capital markets strategy, including preparations for a Nasdaq listing through the MJDS.
"As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority," said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. "Zach brings a wealth of experience across biotechnology financing, public markets and strategic transactions, while Natalia adds strong governance and corporate secretarial expertise. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives."
Zachary Stadnyk added, "I am excited to join Helix at such a pivotal stage in its development. The Company's differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity. I look forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders."
In connection with its ongoing capital markets and governance initiatives, Helix also announced that it is in the process of relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia. The proposed move aligns with the strengthening of the company's governance and capital markets infrastructure as it advances its Nasdaq uplisting strategy under the MJDS framework.
The appointments come at a critical time for Helix, which is focused on advancing its pipeline led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and is finalizing the clinical protocol for L-DOS47. Additionally, Helix is progressing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug.
For more information about Helix BioPharma, visit https://www.helixbiopharma.com/.
